Elite Pharmaceuticals Reports Successful Pivotal

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse-Deterrent Oxycodone Product ELI-201

NORTHVALE, N.J., Dec. 3, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB: ELTP ) announced today successful results from a pivotal bioequivalence (BE) study for ELI-201, Elite's twice daily abuse-deterrent oxycodone product which utilizes Elite's proprietary pharmacological abuse-deterrent technology.

The study, initiated in July of 2014, demonstrated Elite's product is bioequivalent to the branded drug based on pharmacokinetic measures including peak concentration (Cmax) and area under the curve (AUC) as measured for opioid blood plasma levels. The study was a single dose, open label, randomized, cross-over study in healthy volunteers with 34 subjects conducted under fasted conditions   Final findings of bioequivalence are dependent upon FDA review.

ELI-201 is another product in Elite's line of abuse deterrent opioids to pass pivotal bioequivalence studies.  The first Elite product to pass pivotal bioequivalence was ELI-200. A third product in this line, ELI-202 is currently undergoing a pivotal BE study, after having successfully completed a pilot study.

"This successful bioequivalence study marks an important milestone in our development of a full line of abuse resistant opioid products. Our proprietary technology, which has been proven in multiple clinical trials, is the key to Elite's goal of creating a diverse range of abuse-deterrent products and establishing Elite as a leader in the opioid market," commented Nasrat Hakim, Elite's President and CEO. "Our top priority remains the filing of a New Drug Application with the FDA and preparing for the commercial product launch of ELI-200 scheduled for the fourth quarter of 2015."

The bioequivalence studies for these opioid abuse-deterrent products are being conducted under the direction of Camargo Pharmaceutical Services.

About Elite's Abuse-Deterrent Technology

Elite's abuse-deterrent products utilize the Company's proprietary pharmacological abuse-deterrent technology. Elite's abuse-deterrent technology is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist. Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence.  When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers.

About Section 505(b)(2)

The Company plans to file an NDA for this product based on the provisions of section 505(b)(2) of the U.S. Food, Drug & Cosmetic Act.  Section 505(b)(2) allows the FDA to approve a drug on the basis of data in the scientific literature or data previously cited by the FDA as the basis for the approval of related drugs. This procedure makes it easier and potentially faster for drug developers to obtain approval of new formulations of drugs based, in part, on proprietary data of the developer of the original drug.

About Camargo Pharmaceutical Services

Camargo is a full-service drug development partner specializing in the 505(b)(2) process — an approach for developing products that offer differentiated benefits. Camargo is capable of managing every facet of the plan throughout the development continuum, from feasibility assessments, formulation and testing the drug product, to conducting preclinical and clinical studies, to final submission.

About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company developing a pipeline of proprietary pharmacological abuse-deterrent opioid products and niche generic products. Elite specializes in oral sustained and controlled release drug products with high barriers to entry. Elite has seven commercial products currently being sold, twelve additional approved products pending manufacturing site transfer and two additional products under review pending approval by the FDA. Elite's lead pipeline products include abuse-deterrent opioids utilizing the Company's patented proprietary technology, and a once-daily opioid. They are sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also provides contract manufacturing for Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.) and has partnered with Epic Pharma for the manufacturing and distribution of eleven approved products pending manufacturing site transfer, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the United States market and its territories. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Including those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release, readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, its ability to obtain FDA approval of the transfers of the ANDAs or the timing of such approval process, delays, uncertainties, inability to obtain necessary ingredients and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These risks and other factors, including, without limitation, the Company's ability to obtain sufficient funding under the LPC Agreement or from other sources, the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, intellectual property protections and defenses, and the Company's ability to operate as a going concern, are discussed in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q and 8-K. Elite undertakes no obligation to update any forward-looking statements.

Elite Pharmaceuticals, Inc. Dianne Will, Investor Relations, 518-398-6222

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 55

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading
Novo and nference Push Whole-Body Data Into Research

Updated Category News Views 0

Cardiometabolic medicine has spent too long staring at single numbers while the rest of the body keeps waving its arms. Novo Nordisk’s newly announced collaboration with nference is an attempt to widen that lens, combining Novo’s clinical-trial research with nference’s AI technology and federated healthcare data network. The target is not small: obesity, diabetes,...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 159

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 197

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
Yeahka Bids to Lead AI Shopping Evolution

Updated Category News Views 115

AI Shopping: A New Frontier or A Sisyphean Task? The evolution of AI from sassy recommendation tools to transaction-executing agents is shaking up the retail sector. Enter Stage Left: Yeahka Limited (9923.HK), a payment tech outfit that's wading into this murky digital swamp. With YeahPay and Fushi Tech, they're trying to hammer out a blueprint for AI-friendly commerce...

Continue Reading
New Flight Charters Puts a Cap on Winter Surprises

Updated Category News Views 175

Ice on a wing is routine; ice on an invoice is where charter customers start muttering. New Flight Charters says it will again absorb de-icing and hangar charges this winter, up to $2,500 per trip, marking the seventh consecutive season for the program. In a business where the headline quote can look tidy and the final bill can arrive wearing muddy boots, that is a...

Continue Reading
ETCO Targets the Unflashy Weak Link in Battery Storage

Updated Category News Views 0

A battery cabinet can look impressive right up until one lousy connection becomes the problem nobody budgeted for. ETCO Incorporated’s new lineup of standard and custom connectors and terminals goes after that unglamorous part of battery energy storage systems: the physical handoff points carrying power, grounding equipment, and tying auxiliary components together. It...

Continue Reading
ZAKSIMLAB Tests Kombucha and Salmon Snack Pairing in Cafes

Updated Category News Views 148

A fish-based chip beside a fizzy tea mix is an odd little commercial wager, and that is exactly why ZAKSIMLAB's latest move deserves a look. The Seoul food brand launched Salmon Crunch Protein Chips in September, then put the snack next to its powdered kombucha at the 2026 Cafe & Bakery Fair Season 2. This is not a grand earnings story; no sales, pricing, store-count, or...

Continue Reading
Mining's Biodiversity Map Sharpens Location Risks

Updated Category News Views 11

Twelve thousand pins on a map do not settle the mining industry's nature problem, but they do make it much harder to pretend the problem is evenly spread. ICMM's new Global Mining and Metals Biodiversity Dataset overlays 12,000 large-scale formal mining, smelting, refining and processing facilities with ecosystem-condition and conservation indicators. For investors...

Continue Reading
SteriLance Aims for Smoother Pricks with NanoSense Move

Updated Category News Views 72

Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...

Continue Reading

Top 5 Most Recently Viewed Articles

IASO Bio Achieves Major Milestone with Orphan Drug Status

Updated Category News Views 270

IASO Bio Earns Orphan Drug Designation for Breakthrough Therapy IASO Biotherapeutics, a key player in the biopharmaceutical sector, announced an exciting achievement as its groundbreaking treatment, Equecabtagene Autoleucel (Fucaso), received Orphan Drug Designation from the Ministry of Food and Drug Safety. This recognition is particularly significant for adults fighting...

Continue Reading
Transforming Experience: Honda Center's $1 Billion Revamp

Updated Category News Views 387

Transforming Experience: Honda Center's $1 Billion Revamp Honda Center Encore Is A Multi-Year Investment Led by the Samueli Family That Will Redefine the Arena Experience OC Sports & Entertainment (OCSE), connected with the operator of Honda Center, has announced a groundbreaking project known as Honda Center Encore. This ambitious venture involves a significant...

Continue Reading
PIMCO Municipal Income Fund Faces Market Pressures at New Lows

Updated Category News Views 192

PIMCO Municipal Income Fund's Recent Market Performance PIMCO Municipal Income Fund (PMF) has recently faced significant market challenges, as evidenced by its stock hitting a notable 52-week low at a price of $8.82. This decline isn't merely an isolated incident; it reflects ongoing pressures impacting the broader fixed-income sector. Investors are currently navigating...

Continue Reading
Exploring Non-Surgical Solutions for Prostate Health Issues

Updated Category News Views 174

Prostate health became a hot topic for many men over 50, especially with the rise of benign prostatic hyperplasia (BPH)—that uncomfortable enlargement that turns bathroom trips into sprints. Back then, treatment options were shaking up, and PAE was coming onto the scene like it owned the place. PAE vs. Traditional Surgery: The Fight for Relief In an era where...

Continue Reading
Applied Digital Appoints Laura Laltrello as COO for AI Growth

Updated Category News Views 245

Applied Digital Names Laura Laltrello as New COO Applied Digital Corporation (NASDAQ: APLD) is excited to announce the appointment of Laura Laltrello as its new Chief Operating Officer (COO). With an aim to strengthen the Company’s leadership in next-generation data centers and digital cloud solutions, Ms. Laltrello's role signifies a pivotal moment in the Company’s...

Continue Reading